Royalty Report: Drugs, Drug Discovery, Proteins – Collection: 328350

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Drug Discovery
  • Proteins
  • Diagnostic
  • Molecular
  • Disease
  • Therapeutic
  • Medical Info

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 328350

License Grant
For Licensors Screening License, Licensor grants to Licensee of the Netherlands a nonexclusive, worldwide, perpetual license, without the right to grant sublicenses, under Licensor Patent Rights and Technology to use the  Licensor Compounds to screen against any biological targets in the Field.

For Licensors Commercial License, upon notice of Licensees identification of Active Licensor Compounds and disclosure of information to Licensor, and provided that no Third Party Screening Array Partner has already licensed such Active Licensor Compounds in the Field,

Licensor agrees to grant to Licensee an exclusive, worldwide license, with a limited right to sublicense, in the Field under Licensor Patent Rights, under Licensors interest in any Joint Patent Rights and under Licensor Technology, to develop, have developed, make, have made, use, have used, sell and have sold in the Field products incorporating such Active Licensor Compounds.

For the AMAP License, Licensor agrees to grant the licenses to the AMAP Technology, AMAP Chemistry and  Licensor Technology.

For License of AMAP Technology, in the event that Licensee elects to obtain the AMAP Technology, Licensor agrees to grant Licensee a perpetual, non-exclusive license, without the right to sublicense, to use the AMAP Technology, and the Licensor Technology and AMAP Chemistry transferred to Licensee for its own internal research and development efforts on products in the Field.

For the AMAP Improvements, in the event that Licensee elects to obtain the AMAP Technology; Licensor grants a perpetual, non-exclusive license, without the right to sublicense, to use any AMAP Improvements for its own internal research and development efforts on products in the Field.

License Property
Licensor intends to produce compound Arrays containing large numbers of diverse organic compounds.

AMAP shall mean the Automated Molecular Assembly Plant developed by Licensor, which is an integrated system of automated chemical processing substations, automation methods, and information management tools used for combinatorial synthesis, analysis, and purification of organic chemical compounds.

The patents include Oxazolone Derived Materials, Disubstituted Oxazolone Compositions and Derivatives thereof, Aminimide-containing molecules and materials as molecular recognition agents, Aminimide based support materials and functionalized surfaces, Aminimide Compositions and biologically useful derivatives thereof, Directed Chiral Ligands, Recognition agents and functionally useful materials from substituted Aminimides and derivatives containing an asymmetric center, and, Systematic modular production of a Aminimide- and Oxazolone- based molecules having selected propertied; Orthogonal reactive groups.

Field of Use
The proprietary technology relates to the automated assembly and synthesis of Arrays.

IPSCIO Record ID: 299295

License Grant
For the Screening Licenses, Licensor grants, under Licensor Patent Rights and Licensor Technology a nonexclusive license to test each Mapping Arrayâ„¢ for significant functional activity against Targets; and an exclusive license to test each Directed Array for significant functional activity against Targets.

For the Commercialization License., upon the designation of Licensee and upon the designation by the Research Committee of any Active Licensor Compound or any Active Homolog thereto as a Licensed Compound, Licensor shall grant, under any intellecrual property rights owned solely by Licensor or jointly with Licensee or controlled by Licensor including Licensor Patent Rights, Joint Patent Rights and Licensor Technology, covering the composition, manufacture or use of any such Licensed Compound selected by Licensee for Pre-clinical Development, an exclusive, worldwide Iicense upon prompt written notice to Licensor, to develop or have developed Products incorporating Licensed Compounds for use in the Field to make or have made Products incorporating Licensed Compounds for use, distribution and sale in the Field, and to distribute for sale and sell in the Field Products incorporating Licensed Compounds.

License Property
Licensor has developed certain technology that has applications in the discovery and optimization of pharmaceutical compounds.
Field of Use
The Field shall mean, with respect to a Target, all human therapeutic and diagnostic pharmaceutical uses of a Licensed Compound.  Target shall mean any biological target selected by Licensee.

IPSCIO Record ID: 291205

License Grant
By this agreement, Licensor will use its DirectedDiversity Technology to compute a chemical descriptor matrix to describe and map the compounds for which Licensee provides data.  Licensor also will develop a Structure Activity Relationship model based on this descriptor matrix for Hits.  The license during the research period is exclusive.

Licensor grants a worldwide, exclusive license, with right to sublicense, in the Field under such patent to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products, provided that Licensor is not contractually prohibited under a written agreement with a third party from granting such an exclusive license. In the event that Licensor is so contractually prohibited from granting such an exclusive license, Licensor shall grant to Licensee as broad a scope of license as it is permitted (for example, a non-exclusive license) and Licensor shall use its reasonable best efforts to negotiate with such third party to remove such contractual prohibition so as to allow Licensor to grant Licensee the foregoing exclusive license under such Licensor Patents.

For the Unblocking License Grant – Licensor grants a worldwide, nonexclusive license, with right to sublicense, to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensor Compounds, Derivative Compounds, and Licensed Products, under any Licensor patent rights which would otherwise be infringed by Licensee but for this license.

License Property
Licensor is engaged in discovery research for a variety of biologically active compounds and the development of technologies to facilitate such research, and has patented systems for generating chemical compounds having desired pharmaceutical properties.

DirectedDiversity Technology means Licensor Patents and proprietary know-how that relate to generating and utilizing a DirectedDiversity Chemical Library.

DirectedDiversity(R) Chemi-Informatic Technology uses proprietary computer algorithms to design, select and iteratively refine combinatorial libraries of novel, small-molecule drugs based on screening hits obtained from  Licensor or other screening libraries, target-protein 3D structures, or pharmacophore models derived from lead compounds.

Active Compound means a Licensor Compound or Derivative Compound that has been formally selected by Licensee for preclinical and/or clinical development.

Field of Use
Field means human and animal therapeutic and diagnostic imaging uses of compounds against or acting through Targets. The Field for any particular Target will include all therapeutic indications for compounds acting through Targets, including but not limited to the indications identified in the Research Plan.

Licensee is engaged in research and development of human therapeutic products.  The purpose of this collaboration is to identify qualified lead compounds active against selected targets and suitable for medicinal chemistry optimization that may be developed and commercialized by Licensee.

IPSCIO Record ID: 249765

License Grant
For the License to Licensed Products,  Licensor grants an exclusive, even as to Licensor, right and license in the Territory and within the Field under the Licensor Patent Rights and to use the Licensor Know-How to make, have made, use, distribute, promote, market, offer for sale, sell, import and export Licensed Products.

For License to Compounds, Licensor grants an exclusive, even as to Licensor, right and license in the Territory and within the Field under the Licensor Patent Rights and to use the Licensor Know-How to research, develop, make, have made, import, export and use the Selected Compounds, and Active Compounds, Improved Active Compounds and Preliminary Compounds of the same Chemotype as such Selected Compounds, Designated Compounds and Derivative Compounds, for research purposes and to develop Licensed Products.

This agreement also includes non-exclusive grants for research.

License Property
Licensor has certain technology and knowhow, including screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Preliminary Compound means any Compound identified as having binding activity when tested against a Target pursuant to the Screening Program and which has Kd values of 10 micromolar or less (i.e., Kd ~ 1 OµM) or such other binding affinity threshold for a specific Target as shall be agreed upon by the parties in writing.

ALIS means the Automated Ligand Identification System, an automated, ultrahigh throughput ligand selection system proprietary to Licensor that is used to identify multiple classes of chemical ligands against a target protein.

OSCD means Quantisized Surface Complimentary Diversity, a model proprietary to Licensor, in terms of which discrete chemical compliments to the surfaces of a Target are defined.

Licensor Know-How means all proprietary information, data and know-how relating to the NeoMorph Screening Library, NeoMorph Focused Libraries, NeoMorph Chemistry, ALIS, QSCD, the Compounds, Active Compounds, approved Active Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or Licensed Products together with, where applicable, any analogs, derivatives or fragments thereof.

Chemotype means a family or group of Compounds closely structurally related to one or more Active Compounds.

Field of Use
The Field means the treatment or prevention of any disease or condition in humans or animals.

Licensee is interested in identifying potential pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

IPSCIO Record ID: 223155

License Grant
For the Research Program License for Licensor Technology, Licensor hereby grants to German Licensee a worldwide, non-exclusive, irrevocable license under the Licensor Technology during the term of the Research Program to conduct the Research Program.

For Other Licensor Patents, Licensor grants to Licensee irrevocable worldwide, exclusive license in the Field under such patent to make, have made, use, sell, have sold, import and have imported licensed Products, under the conditions stipulated in Article 6, provided that 3DP is not contractually prohibited from granting such an exclusive license.

For ThermoFluor Protein Characterization and Screening Technology, Licensor also grants to Licensee a nonexclusive license under the Licensor Technology to utilize the ThermoFluor Protein Characterization and Screening Technology within the Field also outside of the Research Program.

License Property
The Licensor Technology means patents for System, method, and computer program product for at least partially automatically generating chemical compounds with desired properties from a list of potential chemical compounds to synthesize, and, associated know-how and other intellectual property rights of Licensor that cover the use of DirectedDiversity Accessible Compound Libraries, DirectedDiversity Software Tools and ThermoFluor Protein Characterization and Screening Technology, and other related technology developed by Licensor during the course of this Agreement.

Licensed Product means any commercial product comprising of an Active Compound or a Research Program Compound or a compound synthesized by Licensee and covered by a Compound Patent, provided that the compound synthesized by Licensee results from Optimization Synthesis performed at Licensor on an Active Compound selected for optimization by Licensor.

The Probe library is the collection of discrete, structurally diverse small organic molecules synthesized at the Effective Date from the Accessible Compound Libraries, including additional compounds synthesized subsequently.

The Research Program Compound is a compound that has been synthesized by Licensor in the course of the Research Program, e.g., in the course of optimizing an Active Compound.

Field of Use
The Field means plant management, pest management, including fungi, and animal health, including but not limited to the use of herbicides, plant trait modifiers, plant growth regulators, pesticides, fungicides, animal health care, home and garden products, and environmental health products.  The term Field expressly excludes human diagnostic and human therapeutic products.

IPSCIO Record ID: 253904

License Grant
Licensor grants to English Licensee an exclusive, worldwide, right and license, within the Territory and within the Field, to use the Licensor Know-How and Patent Rights and Licensors undivided interest in any Program Intellectual Property that is jointly owned by the Parties, as embodied in or related to any Designated Compound(s), collectively, the Licensed Technology, to research, develop, make, have made and use such Designated Compound to develop Licensed Products, and, to make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Products.
License Property
The parties pursue a collaborative screening process to identify compounds exhibiting a high degree of chemical binding activity to targets designated by Licensee from among the Licensor libraries of mass-encoded small molecule compounds and which have activity in bioassays or functional assays.

The know-how and patents include screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Licensed Product(s) means any product which includes a Designated Compound or any derivatives, improvements and components thereof; and the development, manufacture, use, or sale.

Licensor Library includes ALIS, the Automated Ligand Identification System, an automated, ultra-high throughput ligand selection system proprietary to the Licensor that is used to identify multiple classes of chemical ligands against target protein.

Field of Use
The Field means the diagnosis or treatment of any disease in humans.  The Licensee is identifying potential pharmaceutical products for treatment of certain human diseases and is identifying compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

IPSCIO Record ID: 299264

License Grant
By this agreement, Licensor shall provide the resources to Licensee and conduct activities under the Research Program. Licensor shall review data and information regarding the Collaboration Target provided by Licensee and derived from the UIL by Licensor, based on such data and information and using the Licensor Technology, design Daughter Libraries; and supply all lead chemistries and synthesize compounds.

Licensee will utilize Licensor Technology for its drug discovery activities under Licensee know-how concerning the identification and characterization of novel small molecule inhibitors.

In addition to Licensees non-exclusive right to use Licensor Technology as necessary to conduct activities under the Research Program, Licensor grants an exclusive, worldwide license, with the right to sublicense to use such Licensor Technology as is necessary to make, have made, use, have used, sell, have sold, import and export Active Compounds, Development Compounds and/or Products in the Territory.

License Property
Licensor has developed, licensed and/or owns certain drug discovery technology and intellectual property rights, including chemical library design software, multi-parallel synthesis and purification methods, chemical libraries suitable for high throughput biological screening assays and medicinal chemistry.

Initial target is Type 3 Phosphodiesterases.

Alternative targets are DNA Polynucleotide kinase (DNA-PK), Poly (ADP-ribase) polymerase (PARP), and, Modulators of the interaction between the G-beta subunit of the G-protein and beta-adrenergic receptor kinase (gB-BARK)

Field of Use
The research focus is for development as therapeutics for treatment of obesity and other diseases in humans.

IPSCIO Record ID: 211827

License Grant
The parties wish to collaborate in a chemical lead and drug discovery program.  This agreement has an exclusive period.  Licensee has a non-exclusive right to use Licensors Technology as necessary to conduct activities under the Research Program.  Additionally, Licensor grants an exclusive, worldwide license, with the right to sublicense to use such Licensor Technology as is necessary to make, have made, use, have used, sell, have sold, import and export Active Compounds, Development Compounds and/or Products in the Territory.
License Property
Licensor has developed, licensed and/or owns certain drug discovery technology and intellectual property rights, including chemical library design software, multi-parallel synthesis and purification methods, chemical libraries suitable for high throughput biological screening assays and medicinal chemistry (collectively, 'CombiChem Technology').

Licensee desires to utilize CombiChem Technology for its drug discovery activities under Licensee know-how concerning the identification and characterization of novel small molecule inhibitors for development as therapeutics for treatment of diseases in humans.

Licensee and its Affiliates have developed and own certain drug discovery and intellectual property rights, including certain assays, methods and know how regarding the Initial Target, among other things (collectively 'ICOS Technology').

The Product means any product containing an Active Compound or Development Compound with such compound as the active ingredient or one of the active ingredients, which is the subject of one or more claims under a Collaboration Patent and which is granted regulatory approval by the governing health regulatory authority of the applicable country for marketing in the Field.

The Product means any product containing an Active Compound or Development Compound with such compound as the active ingredient or one of the active ingredients, which is the subject of one or more claims under a Collaboration Patent and which is granted regulatory approval by the governing health regulatory authority of the applicable country for marketing in the Field.

Field of Use
The Field means all therapeutic indications in humans for any Target against which a Collaboration Compound, Active Compound, Development Compound or Products may be directed.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.